These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 32573795)

  • 21. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults.
    Boinpally R; Trugman J
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):688-695. PubMed ID: 38261231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.
    Depré M; Macleod C; Palcza J; Behm M; de Lepeleire I; Han T; Panebianco D; Smith W; Blanchard R; Chodakewitz J; Murphy M; de Hoon J
    Cephalalgia; 2013 Dec; 33(16):1292-301. PubMed ID: 23798725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
    Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
    J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
    Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
    Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
    Dodick DW; Goadsby PJ; Schwedt TJ; Lipton RB; Liu C; Lu K; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Dec; 402(10419):2307-2316. PubMed ID: 37979595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
    Nedd M; Garland S; Falk N; Wilk A
    Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral sumatriptan for acute migraine.
    McCrory DC; Gray RN
    Cochrane Database Syst Rev; 2003; (3):CD002915. PubMed ID: 12917936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.
    Gutman D; Hellriegel E; Aycardi E; Bigal ME; Kunta J; Chitra R; Kansagra S; Kidron OS; Knebel H; Linder S; Ma Y; Pierce M; Winner PK; Spiegelstein O
    Headache; 2016 Sep; 56(8):1300-9. PubMed ID: 27474357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WITHDRAWN: Oral sumatriptan for acute migraine.
    McCrory DC; Gray RN
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD002915. PubMed ID: 22336784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world efficacy, tolerability, and safety of ubrogepant.
    Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
    Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
    Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
    Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
    Göbel H; Winter P; Boswell D; Crisp A; Becker W; Hauge T; Mihout B; Niewold J; Tørring J
    Clin Ther; 2000 Aug; 22(8):981-9. PubMed ID: 10972634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.
    Navratilova E; Behravesh S; Oyarzo J; Dodick DW; Banerjee P; Porreca F
    Cephalalgia; 2020 Aug; 40(9):892-902. PubMed ID: 32615788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ubrogepant to treat migraine.
    Dhir A
    Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.